Ligand Pharmaceuticals Incorporated (LGND) Institutional Ownership & Insider Trading

415 institutions reported holding Ligand Pharmaceuticals Incorporated shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 136 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

LGNDLigand Pharmaceuticals IncorporatedFollow LGND — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 6.1B
P/E TTM: 32.3
Dividend yield: —
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

415 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +9.2%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	415	23	+9.2%	142	79	101	26
Mar 26	353	21	+0.9%	118	40	101	35
Dec 25	345	21	-3.0%	98	49	106	19
Sep 25	306	21	+7.7%	91	51	86	11
Jun 25	268	19	+2.9%	97	26	70	18
Mar 25	257	19	+2.5%	91	23	75	25
Dec 24	251	18	+0.4%	95	29	53	15
Sep 24	239	18	+4.9%	90	28	47	21

Ligand Pharmaceuticals Incorporated — questions

Who owns Ligand Pharmaceuticals Incorporated stock?: 415 institutions reported Ligand Pharmaceuticals Incorporated shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (15.6%), Invesco Ltd. (6.0%), VANGUARD PORTFOLIO MANAGEMENT LLC (5.7%).
Are Ligand Pharmaceuticals Incorporated insiders buying or selling?: 136 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Ligand Pharmaceuticals Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.